As the TP53 gene is widely inactivated for its tumor-suppressive function in a number of cancers, and TP53 mutation has been reported to confer resistance to cancer therapies, its reactivation or restoration may be a highly attractive therapeutic target for treating the disease, resulting in tumor regression [28]. The gene discussed is TP53; the disease is cancer.